Caseware UK (AP4) 2023.0.135 2023.0.135 2024-06-302024-06-30false32023-07-01falsefalse3trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 13058937 2023-07-01 2024-06-30 13058937 2022-07-01 2023-06-30 13058937 2024-06-30 13058937 2023-06-30 13058937 c:Director1 2023-07-01 2024-06-30 13058937 c:Director3 2023-07-01 2024-06-30 13058937 d:CurrentFinancialInstruments 2024-06-30 13058937 d:CurrentFinancialInstruments 2023-06-30 13058937 d:CurrentFinancialInstruments d:WithinOneYear 2024-06-30 13058937 d:CurrentFinancialInstruments d:WithinOneYear 2023-06-30 13058937 d:ShareCapital 2024-06-30 13058937 d:ShareCapital 2023-06-30 13058937 d:RetainedEarningsAccumulatedLosses 2024-06-30 13058937 d:RetainedEarningsAccumulatedLosses 2023-06-30 13058937 c:FRS102 2023-07-01 2024-06-30 13058937 c:AuditExempt-NoAccountantsReport 2023-07-01 2024-06-30 13058937 c:FullAccounts 2023-07-01 2024-06-30 13058937 c:PrivateLimitedCompanyLtd 2023-07-01 2024-06-30 13058937 e:PoundSterling 2023-07-01 2024-06-30 iso4217:GBP xbrli:pure

Registered number: 13058937










THEPHARMACLINIC LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 JUNE 2024

 
THEPHARMACLINIC LIMITED
REGISTERED NUMBER: 13058937

STATEMENT OF FINANCIAL POSITION
AS AT 30 JUNE 2024

2024
2023
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
3,648
5,761

Cash at bank and in hand
  
78
176

  
3,726
5,937

Creditors: amounts falling due within one year
 5 
(2,640)
(1,230)

Net current assets
  
 
 
1,086
 
 
4,707

Total assets less current liabilities
  
1,086
4,707

  

Net assets
  
1,086
4,707


Capital and reserves
  

Called up share capital 
  
10,000
10,000

Profit and loss account
  
(8,914)
(5,293)

  
1,086
4,707


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 28 March 2025.


Mr J W Foreman
Professor K P Moore
Director
Director

The notes on pages 2 to 3 form part of these financial statements.

Page 1

 
THEPHARMACLINIC LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

1.


General information

THEPHARMACLINIC Limited is a private company, limited by share capital, incorporated in England & Wales under registration number 13058937. The address of the registered office is situated at Level 5A, Maple House, 149 Tottenham Court Road, London, W1T 7NF.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

The financial statements have been prepared on the assumption that the company will have the continued financial support of the shareholders. The shareholders of the company have sufficient resources to finance the company as and when the need arises.
The financial statements have been prepared on a going concern basis which is dependent on the financial support of the shareholders to ensure that the company will continue in operational existence for the foreseeable future.

 
2.3

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.4

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 2

 
THEPHARMACLINIC LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024

3.


Employees

The average monthly number of employees, including directors, during the year was 3 (2023 - 3).


4.


Debtors

2024
2023
£
£


Amounts owed by associated company
3,648
5,761

3,648
5,761



5.


Creditors: Amounts falling due within one year

2024
2023
£
£

Trade creditors
1,410
-

Accruals and deferred income
1,230
1,230

2,640
1,230


 
Page 3